D.P. Medicare Clinical Laboratories Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 03-01-2025
- Paid Up Capital ₹ 0.18 M
as on 03-01-2025
- Company Age 20 Year, 9 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 1.63 Cr
as on 03-01-2025
- Revenue -25.21%
(FY 2020)
- Profit -56.95%
(FY 2020)
- Ebitda -15.24%
(FY 2020)
- Net Worth 7.42%
(FY 2020)
- Total Assets -6.24%
(FY 2020)
About D.P. Medicare Clinical Laboratories
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.18 M.
The company currently has active open charges totaling ₹1.63 Cr.
Reeta Chakrawarty, Dev Chakrabarty, Shweta Chakrabarty, and One other member serve as directors at the Company.
- CIN/LLPIN
U85110UP2004PTC028465
- Company No.
028465
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Mar 2004
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Varanasi, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at D.P. Medicare Clinical Laboratories?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Reeta Chakrawarty  | Director | 31-Mar-2004 | Current |
| Dev Chakrabarty | Director | 31-Mar-2004 | Current |
| Shweta Chakrabarty | Director | 31-Mar-2004 | Current |
| Saurabh Chakrabarty | Director | 31-Mar-2004 | Current |
Financial Performance of D.P. Medicare Clinical Laboratories.
D.P. Medicare Clinical Laboratories Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 25.21% decrease. The company also saw a substantial fall in profitability, with a 56.95% decrease in profit. The company's net worth moved up by a moderate rise of 7.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of D.P. Medicare Clinical Laboratories?
In 2020, D.P. Medicare Clinical Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of Baroda Creation Date: 23 Sep 2015 | ₹2.00 M | Open |
Hdfc Bank Limited Creation Date: 21 Jun 2015 | ₹0.69 M | Open |
Others Creation Date: 30 Aug 2014 | ₹1.24 Cr | Open |
How Many Employees Work at D.P. Medicare Clinical Laboratories?
Unlock and access historical data on people associated with D.P. Medicare Clinical Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of D.P. Medicare Clinical Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped D.P. Medicare Clinical Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
